Medical News Today1d
Lenacapavir injection lowers HIV risk by 96%
Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...
Daily3h
Clinical trial reveals twice-yearly injection to be 96% effective in HIV prevention
For oral medications that prevent new HIV infection to be effective, the patient must take certain actions, including ...
HIV prophylactic lenacapavir — very safe and very expensive
Health experts say lenacapavir could reduce the number of global HIV infections significantly. But it needs to be cheaper to ...
Labroots13h
Twice Yearly Injection 96% Reduces HIV Infection Risk by 96%
A recent phase 3 trial found that twice-yearly injections of Lenacapavir reduce the risk of contracting HIV by 96%. | Drug ...
A twice-yearly shot could help end AIDS. But will it get to everyone who needs it?
Drugmaker Gilead said it will allow cheap, generic versions to be sold in 120 poor countries with high HIV rates, mostly in ...
India Today on MSN1d
New injection reduces risk of HIV infection by 96%: All about it
A new HIV prevention method, Lenacapavir, administered as a twice-yearly injection, has demonstrated superior results ...
Medscape19h
HIV ‘Game-Changer’ Drug: Is Eastern Europe Missing Out?
In the PURPOSE 2 trial, lenacapavir offered almost complete protection to cisgender men, transgender women, transgender men, ...
Six-Month HIV Prevention Shot Achieves 99% Efficacy in Major Study
Lenacapavir, a new twice-yearly injection, offers 96% HIV prevention efficacy, surpassing daily oral PrEP. For oral ...
HIV Breakthrough as New Injection 89% More Effective Than PrEP
"PrEP reduces the risk of getting HIV from sex by about 99 percent when taken as prescribed. Although there is less ...
clinicaltrialsarena6d
Gilead’s twice-yearly lenacapavir shows promise in HIV prevention trial
Gilead Sciences has announced the outcomes from the Phase III PURPOSE 2 trial evaluating lenacapavir for HIV prevention.